| |
Change from baseline
|
Repeated measures two-way ANOVA
|
|---|
|
Week 4
|
Week 8
|
Week 12
|
Group
|
Time
|
Interaction
|
|---|
|
Mean
|
SD
|
Mean
|
SD
|
Mean
|
SD
|
|---|
|
CRP, mg/dL
|
|
Placebo
|
0.019
|
0.044
|
0.036
|
0.091
|
0.016
|
0.047
|
0.057
|
0.363
|
0.302
|
|
CLE
|
0.021
|
0.089
|
0.002
|
0.032
|
−0.007*
|
0.035
|
|
C3, mg/dL
|
|
Placebo
|
4.13
|
7.94
|
0.10
|
9.33
|
7.26
|
9.00
|
0.514
|
< 0.001
|
0.138
|
|
CLE
|
4.00
|
8.14
|
1.41
|
11.90
|
2.66*
|
8.20
|
|
C4, mg/dL
|
|
Placebo
|
0.06
|
2.78
|
0.71
|
3.57
|
1.48
|
3.47
|
0.366
|
0.094
|
0.135
|
|
CLE
|
0.28
|
2.58
|
−0.07
|
3.42
|
0.34
|
2.69
|
|
Fibrinogen, mg/dL
|
|
Placebo
|
9.0
|
27.9
|
11.4
|
46.3
|
15.1
|
35.5
|
0.648
|
0.371
|
0.950
|
|
CLE
|
5.3
|
50.6
|
3.7
|
29.7
|
12.0
|
37.8
|
- CRP: C-reactive protein; C3: complement component 3; C4: complement component 4
- aValues represent the means and standard deviations at 4, 8, and 12 weeks for n = 31, 31, and 31 (placebo group) or n = 29, 27, and 29 (CLE group), respectively. *p < 0.05: Significant difference from the placebo group by repeated measures two-way ANOVA, followed by the two-tailed unpaired Student’s t test when variance was homogeneous or the Aspin-Welch t test when variance was heterogeneous
